BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8363402)

  • 1. Serum soluble interleukin 2 receptor levels in erythrodermic cutaneous T-cell lymphoma correlate with response to photopheresis-based treatment.
    Goldman BD; Oh SK; Davis BE; Kadin ME; Poiesz BJ; Koh HK
    Arch Dermatol; 1993 Sep; 129(9):1166-70. PubMed ID: 8363402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased serum concentration of the soluble interleukin-2 receptor in cutaneous T-cell lymphoma. Clinical and prognostic implications.
    Wasik MA; Vonderheid EC; Bigler RD; Marti R; Lessin SR; Polansky M; Kadin ME
    Arch Dermatol; 1996 Jan; 132(1):42-7. PubMed ID: 8546482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis.
    Miyagaki T; Sugaya M
    J Dermatol Sci; 2011 Oct; 64(1):1-6. PubMed ID: 21872448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extracorporeal photopheresis for the treatment of erythrodermic cutaneous T-cell lymphoma: a single center clinical experience with long-term follow-up data and a brief overview of the literature.
    Quaglino P; Knobler R; Fierro MT; Savoia P; Marra E; Fava P; Bernengo MG
    Int J Dermatol; 2013 Nov; 52(11):1308-18. PubMed ID: 23786842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival in erythrodermic cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of patients with erythrodermic cutaneous T-cell lymphoma.
    Vidulich KA; Talpur R; Bassett RL; Duvic M
    Int J Dermatol; 2009 Mar; 48(3):243-52. PubMed ID: 19261011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
    Edelson RL
    Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultraviolet-B phototherapy for early-stage cutaneous T-cell lymphoma.
    Ramsay DL; Lish KM; Yalowitz CB; Soter NA
    Arch Dermatol; 1992 Jul; 128(7):931-3. PubMed ID: 1626959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy.
    Ferenczi K; Yawalkar N; Jones D; Kupper TS
    Arch Dermatol; 2003 Jul; 139(7):909-13. PubMed ID: 12873887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case report of four patients with erythrodermic cutaneous T-cell lymphoma and severe photosensitivity mimicking chronic actinic dermatitis.
    Agar N; Morris S; Russell-Jones R; Hawk J; Whittaker S
    Br J Dermatol; 2009 Mar; 160(3):698-703. PubMed ID: 19067712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extracorporeal photochemotherapy in patients with cutaneous T-cell lymphoma: is clinical response predictable?
    Rao V; Ryggen K; Aarhaug M; Dai HY; Jørstad S; Moen T
    J Eur Acad Dermatol Venereol; 2006 Oct; 20(9):1100-7. PubMed ID: 16987266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ECP versus PUVA for the treatment of cutaneous T-cell lymphoma.
    Geskin L
    Skin Therapy Lett; 2007 Jun; 12(5):1-4. PubMed ID: 17609808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven Hospital experience.
    Heald PW; Perez MI; Christensen I; Dobbs N; McKiernan G; Edelson R
    Yale J Biol Med; 1989; 62(6):629-38. PubMed ID: 2534648
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase activity and telomere length in lymphocytes from patients with cutaneous T-cell lymphoma.
    Wu K; Lund M; Bang K; Thestrup-Pedersen K
    Cancer; 1999 Sep; 86(6):1056-63. PubMed ID: 10491534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma.
    Heald P; Yan SL; Edelson R
    Arch Dermatol; 1994 Feb; 130(2):198-203. PubMed ID: 8304758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of interleukin-18 and caspase-1 in cutaneous T-cell lymphoma.
    Yamanaka K; Clark R; Dowgiert R; Hurwitz D; Shibata M; Rich BE; Hirahara K; Jones DA; Eapen S; Mizutani H; Kupper TS
    Clin Cancer Res; 2006 Jan; 12(2):376-82. PubMed ID: 16428475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of cutaneous T-cell lymphoma.
    Zackheim HS
    Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. "High-dose" UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides.
    Zane C; Leali C; Airò P; De Panfilis G; Pinton PC
    J Am Acad Dermatol; 2001 Apr; 44(4):629-33. PubMed ID: 11260537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extracorporeal photochemotherapy alone or with adjuvant therapy in the treatment of cutaneous T-cell lymphoma: a 9-year retrospective study at a single institution.
    Bisaccia E; Gonzalez J; Palangio M; Schwartz J; Klainer AS
    J Am Acad Dermatol; 2000 Aug; 43(2 Pt 1):263-71. PubMed ID: 10906649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis.
    Lim HW; Harris HR
    Dermatol Surg; 1995 Jul; 21(7):597-9. PubMed ID: 7606369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenin levels are increased in lesional skin and sera in patients with erythrodermic cutaneous T cell lymphoma.
    Miyagaki T; Sugaya M; Suga H; Akamata K; Ohmatsu H; Fujita H; Asano Y; Tada Y; Kadono T; Sato S
    Arch Dermatol Res; 2012 Jul; 304(5):401-6. PubMed ID: 22526325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.